Form 4: Ocular Therapeutix Director Merilee Raines Receives Significant Equity Grants

Ocular Therapeutix, Inc. Director Merilee Raines was granted 14,000 restricted stock units and 44,000 stock options as part of her compensation, aligning her interests with shareholders.

Summary

• Merilee Raines, a Director of Ocular Therapeutix, Inc. (OCUL), received a grant of 14,000 restricted stock units (RSUs) on June 11, 2025.
• Each RSU represents a right to receive one share of the company's common stock.
• The RSUs will vest 100% on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders, subject to continued service.
• Additionally, Ms. Raines was granted 44,000 stock options on June 11, 2025, with an exercise price of $8.82 per share.
• These stock options will also vest 100% on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders, subject to continued service.
• The stock options have an expiration date of June 10, 2035.
• Following these transactions, Merilee Raines beneficially owns 46,933 shares of common stock and 44,000 derivative securities (stock options).
• An Exhibit 24 Power of Attorney was filed, authorizing designated individuals to handle SEC filings on behalf of Merilee Raines.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates standard compensation practices and aligns director interests with shareholders, with no negative implications found in the filing itself.

Positives

• The equity grants align the director's financial interests with those of the company's shareholders, incentivizing long-term performance.
• The grants are part of a standard compensation plan (2021 Stock Incentive Plan), indicating routine corporate governance practices.

Future Outlook

The granted RSUs and stock options are subject to vesting conditions, requiring Merilee Raines' continued service on the company's board of directors. Vesting will occur 100% on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, a common practice across various industries to incentivize leadership and align their interests with long-term company performance. It does not provide specific insights into broader industry trends beyond standard corporate governance.

Corporate Governance

Related Party Transactions

• The grant of 14,000 Restricted Stock Units and 44,000 Stock Options to Merilee Raines, a director of Ocular Therapeutix, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing shareholder value.
• Employees: No direct impact on general employees is indicated by this filing, though it reflects the company's compensation practices for its leadership.

Next Steps

• Continued service of Merilee Raines on the board of directors for the RSUs and options to vest.
• Vesting of RSUs and stock options on the first anniversary of the grant date or prior to the next annual meeting of stockholders.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Merilee Raines, SEC Form 4, Restricted Stock Units, Stock Options, Insider Trading, Equity Compensation, Director Compensation, SEC Filing